On May 31, 2022 VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, reported that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview and participate in investor meetings at the upcoming Jefferies Healthcare Conference being held in New York on June 8 – 10, 2022 (Press release, VBL Therapeutics, MAY 31, 2022, View Source [SID1234615270]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Jefferies Healthcare Conference
Date: Wednesday, June 8th, 2022
Time: 3:00 p.m. ET
Format: Corporate Overview
Webcast Link
A replay of the webcast will be available following the presentation for 90 days on the Events and Presentations page of the Investors section on the Company’s website at www.vblrx.com.